Tag Archives: nivolumab

Immunotherapy as Effective Second-Line Treatment for Mesothelioma

Effective Second-Line Treatment for Mesothelioma

A study from Taiwan has identified an effective second-line treatment for malignant pleural mesothelioma. When a patient is diagnosed with mesothelioma and begins treatment, the first treatment is called the “first-line treatment.” If that treatment does not work or stops working, a “second-line treatment” is given to the patient. For mesothelioma, treatment usually consists of surgery, chemotherapy, and radiation. The exact treatment plan will depend on many factors. Doctors will consider the type of mesothelioma, the condition of the patient, and how much the cancer has spread. A common first-line treatment for mesothelioma patients is chemotherapy with drugs called pemetrexed and cisplatin. When this treatment works properly, it stops cancer cells from growing and multiplying. It is for patients whose … Continue reading Immunotherapy as Effective Second-Line Treatment for Mesothelioma »

Immune Checkpoint Therapy for Mesothelioma

Immune Checkpoint Therapy for Mesothelioma

A new study suggests that immune checkpoint therapy with nivolumab is a promising treatment for a specific type of mesothelioma. The study authors describe three cases of sarcomatoid mesothelioma being treated with nivolumab at Kyoto University Hospital in Japan. A Deadly Form of Mesothelioma There are three types of malignant pleural mesothelioma. They each respond differently to mesothelioma treatments. One of these types is sarcomatoid mesothelioma and it is the rarest type of mesothelioma. Sarcomatoid pleural mesothelioma cells are slender ovals with large or even multiple nuclei. Because these cells are spindle-shaped, this type of mesothelioma is sometimes called spindle-cell mesothelioma. Sarcomatoid mesothelioma is an especially deadly form of the disease. This type grows and spreads faster than the other … Continue reading Immune Checkpoint Therapy for Mesothelioma »

Drug Combo Nivolumab plus ipilimumab Has Best Survival Rates in Relapsed Mesothelioma

Drug Combo Nivolumab plus ipilimumab Has Best Survival Rates in Relapsed Mesothelioma

Malignant pleural mesothelioma is an aggressive cancer with limited therapeutic options. Pemetrexed plus platinum is often the first treatment option that clinicians turn to. There are now several options for second treatment therapy. This is useful in patients with relapsed mesothelioma. Yet some of these treatment therapies remain controversial. Several drugs were recently introduced to treat relapsed mesothelioma. A new study conducted a meta-analysis to check the efficacy of these drugs. After Chemotherapy, What Comes Next? Nivolumab alone or nivolumab plus ipilimumab provided significantly longer patient survival. In fact, treatment with nivolumab plus ipilimumab was found to have the best survival rates. Other treatments had a good survival rate compared with a placebo. These other treatments included tremelimumab, vorinostat, and chemotherapy … Continue reading Drug Combo Nivolumab plus ipilimumab Has Best Survival Rates in Relapsed Mesothelioma »

Nivolumab + Ipilimumab Provides Long-Term Survival Benefit in Malignant Pleural Mesothelioma

Nivolumab + Ipilimumab Provides Long-Term Survival Benefit

Nivolumab + ipilimumab continues to provide a long-term survival benefit in malignant pleural mesothelioma. A new report shows a 3-year follow-up in the CheckMate Clinical Trial. Long-term clinical benefits remained the same for all patient groups. Background on the Nivolumab + Ipilimumab Treatment Two years ago, the FDA approved the combination of nivolumab + ipilimumab. It is the first-line treatment for patients with metastatic non-small cell lung cancer. The CHECKMATE randomized multi-part trial investigated the effectiveness. The trial showed a significant improvement in patient survival. Today, this treatment combination improves patient survival rates over chemotherapy. Mesothelioma patients showed an improved survival using this line of treatment. A new report from the Annals of Oncology describes updated data with at least … Continue reading Nivolumab + Ipilimumab Provides Long-Term Survival Benefit in Malignant Pleural Mesothelioma »

Relapsed Mesothelioma Patients Live Longer on Opdivo in Phase 3 Trial

relapsed mesothelioma patients

A multi-center British study suggests that the cancer drug Opdivo (nivolumab) may be a solid second-line treatment option for relapsed mesothelioma patients.  The Phase-3 trial involved mesothelioma patients from 24 UK hospitals. All had an ECOG score of 0 or 1, meaning they were in reasonably good health overall.  All of the patients had first-line treatment with platinum-based chemotherapy. Then their cancer came back. There is no approved treatment for relapsed mesothelioma patients. So these patients enrolled in the nivolumab trial.  Although Opdivo is not a cure for mesothelioma, the results of the news trial show it could extend survival for the right patients.  How Does Opdivo Work? Nivolumab is sold under the brand name Opdivo. It is an immunotherapy … Continue reading Relapsed Mesothelioma Patients Live Longer on Opdivo in Phase 3 Trial »

Yervoy and Opdivo for Mesothelioma: Three Year Results Still Look Good

Yervoy and Opdivo for mesothelioma

Three years after the last patients enrolled in the clinical trial of Yervoy and Opdivo for mesothelioma, survival results still look promising for this immunotherapy treatment.  Researchers presented an update of the CheckMate 743 trial at the recent virtual conference of the European Society for Medical Oncology (ESMO). The team found that more than 23% of patients on Yervoy and Opdivo for mesothelioma were still alive at three years. Only 15% of the chemotherapy group were still living.  Immunotherapy for Malignant Mesothelioma Alimta (pemetrexed) was the first drug to receive FDA approval for mesothelioma chemotherapy. The FDA approved it in 2004.  Before Alimta, patients had even fewer options that they do today. Most mesothelioma patients now start treatment with a … Continue reading Yervoy and Opdivo for Mesothelioma: Three Year Results Still Look Good »

Opdivo as Second-Line Treatment Option for Mesothelioma: Promising New Data

second-line treatment option

A new study suggests that the cancer drug Opdivo could be an effective second-line treatment option for people with relapsed mesothelioma. Right now, people whose mesothelioma comes back after treatment do not have an approved second-line treatment option.  The news on Opdivo comes from the first ever placebo-controlled phase 3 trial of patients with relapsed mesothelioma. It shows that the drug significantly improved overall survival for these patients. It also increased the time it took for patients’ cancer to get worse. Details of the CONFIRM Trial The trial of this proposed second-line treatment option for mesothelioma was called CONFIRM. It involved 332 mesothelioma patients from 24 UK cancer centers. The patients already had at least one treatment. Two thirds of … Continue reading Opdivo as Second-Line Treatment Option for Mesothelioma: Promising New Data »

Study to Test Nivolumab and Chemotherapy for Mesothelioma

Nivolumab and Chemotherapy

Researchers in Germany are recruiting patients for a trial of nivolumab and chemotherapy for pleural mesothelioma patients who have had surgery. Nivolumab (Opdivo) is an immunotherapy drug similar to pembrolizumab (Keytruda). It blocks a protein that helps mesothelioma cells hide from the immune system. Nivolumab is most often used for patients with non-small cell lung cancer. The multicenter German study will test if a combination of nivolumab and chemotherapy can help keep tumors from growing back after mesothelioma surgery. Previous studies suggest that it has the potential to do so. How Immune Checkpoint Inhibitors Work Immune checkpoint inhibitors like nivolumab, pembrolizumab, and ipilimumab (Yervoy) are a major focus for mesothelioma researchers. Mesothelioma cells are notoriously tenacious. They often fail to … Continue reading Study to Test Nivolumab and Chemotherapy for Mesothelioma »

New Drug Combination for Mesothelioma Wins FDA Approval

New Drug Combination for Mesothelioma

The FDA has approved a new drug combination for mesothelioma. It is the first systemic treatment for mesothelioma to win FDA approval in 16 years.  The combination includes a pair of immunotherapy drugs that complement each other. Both drugs are immune checkpoint inhibitors. They are approved to treat people with inoperable pleural mesothelioma.  “Today’s approval of nivolumab plus ipilimumab provides a new treatment that has demonstrated an improvement in overall survival for patients with malignant pleural mesothelioma,” says Richard Pazdur, MD, director of the FDA’s Oncology Center of Excellence. New Treatment Options Needed Pleural mesothelioma is a virulent cancer of the membrane that surrounds the lungs. Asbestos exposure is usually the trigger. Many countries have banned asbestos. In the US, … Continue reading New Drug Combination for Mesothelioma Wins FDA Approval »

“Exceptional Survival” in Some Patients on Nivolumab for Mesothelioma

The Challenges of Diagnosing Mesothelioma

A real-world study of Dutch patients suggests that nivolumab for mesothelioma can dramatically extend survival in the right patients.  Nivolumab is sold under the brand name Opdivo. It is a type of immunotherapy. It works by making cancer cells more vulnerable to attack. The FDA approved nivolumab to treat non-small cell lung cancer and some other cancers.  It is still in the testing phase for malignant mesothelioma. The new report suggests that careful patient selection is the key to making nivolumab for mesothelioma work.  Why Nivolumab for Mesothelioma? Malignant mesothelioma is an aggressive cancer caused by past exposure to asbestos. Like other types of cancer, it has ways of protecting itself from immune system attack. A protein called PD-L1 is … Continue reading “Exceptional Survival” in Some Patients on Nivolumab for Mesothelioma »